Therapeutic Advances in Reproductive Health delivers the highest quality peer-reviewed original research articles, reviews, and scholarly comment on pioneering efforts and innovative studies in the field of reproductive health and medicine. The journal is aimed at an international audience of clinicians and researchers, providing an online forum for rapid dissemination of recent research and perspectives. Subjects covered include (but are not limited to):

• Fertility and Sterility

• Infertility and Assisted Reproductive Technology (e.g., in vitro fertilisation [IVF], intracytoplasmic sperm injection [ICSI], ovulation induction, artificial insemination, donor conception, gamete intrafallopian transfer, preimplantation genetic testing, surrogacy)

• Fertility preservation

• Paediatric and Adolescent Gynaecology

• Menstruation and pre-menstrual tension

• Contraception

• Pregnancy (issues pertaining to the mother and to embryonic/foetal development)

• Childbirth and Post-natal care

• Post-partum depression

• Menopause and Hormone replacement therapy (HRT)

• Women's Health

• Infections and disease

• Gynecologic oncology/Reproductive cancers

• Obstetrics/Gynaecology, including Ob/Gyn Surgery

• Andrology

• Pelvic floor problems

• Pelvic inflammatory disease (PID)

• Endometriosis

• Polycystic ovary syndrome (PCOS)

• Environmental impacts on reproduction

The journal is dedicated to publishing clinical research. We do not publish preclinical research, including basic laboratory research and animal studies.

Review articles include expert opinion/perspective reviews (including single-drug and drug class reviews), narrative reviews and therapeutic area reviews. Systematic reviews, meta-analyses, post-marketing and health economic and pharmacoeconomic reviews are also welcomed. The appropriate EQUATOR Network reporting guidelines should be followed (e.g. CONSORT for randomized, controlled trials and PRISMA for systematic reviews/meta-analyses). The journal endorses the ICMJE requirement that clinical trials are registered in a WHO-approved public trials registry at or before the time of first patient enrolment.

The journal adheres to a single-blind review process in which the reviewer's name is routinely withheld from the author unless the reviewer requests a preference for their identity to be revealed. Manuscripts are reviewed by at least two referees.